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Objectives: Reimbursement systems are evolving and endeavour to balance access and 
affordability. One such evolution in Ireland is the compulsory Rapid Review (RR) 
process, the outcome from which is a recommendation for a health technology 
assessment (HTA) or no HTA. For drugs that avoid a HTA, evaluation times are 
shorter, lengthy price negotiations are avoided and access is faster.  
 
In the absence of formal decision-making criteria around the requirement of a HTA, 
this study examines the factors influencing the outcome of the RR process in Ireland.  
 
Methods: A database was developed combining data from publicly available sources 
for drug evaluations conducted by the National Centre for PharmacoEconomics 
(NCPE) (January 2010-June 2017, (n=296)). As Irish cost data were not publicly 
available for all drugs, cost data from the Scottish Medicines Consortium was employed 
as a proxy. Employing logitistic regressions the factors influencing the RR outcome are 
revealed.  
 
Results: Following a RR, a HTA was recommended for 55% of drugs. Regression 
results revealed therapeutic area (endocrine, musculoskeletal and neoplasm), first-in-
class and orphan disease increased the probability of a HTA. Furthermore, when proxy 
costs were included, results revealed that every €1,000 increase in annual drug costs 
per patient increased the probability of a HTA being required by 1% and that a HTA 
was more likely than no HTA when annual drug costs exceeded €15,000.  
 
Conclusion: Given the current focus on access and affordability, this study identifies 
the factors influencing the requirement of a HTA in Ireland.  
 
HIGHLIGHTS 
1. Since 2010 Rapid Reviews are compulsory for any drug seeking reimbursement 
in Ireland.  This unique approach is a means of achieving balance between 
optimising agency resources, providing patients faster access to medicines and 
ensuring affordability. Exploring reimbursement approaches and sharing 
experiences can be meaningful for HTA agencies designing and evolving their 
systems, particularly given the shift towards value based frameworks for 
reimbursement.  
2. In Ireland a rapid review is submitted for all drugs seeking reimbursement; 
following this 55% of submissions are recommended for a full health 
technology assessment (HTA). This study describes the RR process employed 
in Ireland and indicates the factors influencing the requirement of a HTA to 
secure reimbursement, namely therapeutic area, first in class, orphan status and 
patient drug costs. 
3. Establishing formal decision-making criteria around the requirement for a full 
HTA could contribute to better management for the introduction of new drugs 
particularly given current and expected future trends of high cost drugs and 
delays in access to medicines, suggest better management for their introduction 
is warranted.  
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1 INTRODUCTION  
 
Reimbursement and health technology assessment (HTA) systems globally evolve in 
response to environmental and economic challenges. In particular, since the global 
financial crisis, efforts to balance access and affordability are prioritised. A somewhat 
unique approach was taken in Ireland with the introduction of compulsory Rapid 
Reviews (RR) in 2010.  While employed in a variety of countries to support decision 
making, the definition and implementation of RRs vary in practice [1]. However, most 
RRs aim to synthesise evidence in a timely manner without sacrificing scientific rigour 
[2].  
 
Prior to this only medicines with a significant budgetary impact were considered for a 
HTA in Ireland, albeit there was no explicit threshold on what constituted a significant 
budget impact. However as the financial crisis hit Ireland and recession ensued, budget 
cuts were necessary. The volume of medicines to be assessed increased at the same time 
and so did evaluation times. RRs were therefore introduced [3] as a means of optimising 
agency resources, which led to shorter evaluation times and faster patient access while 
ensuring affordability.  
 
Access and affordability of medicines are longstanding issues, particularly in Ireland, 
where per capita pharmaceutical expenditure increased dramatically from the 20th 
highest of 27 OECD countries in 2000 to 3rd highest of 25 OECD countries in 2010 [4]. 
Following the introduction of international and internal reference pricing, 
pharmaceutical spend moderated in Ireland but like other countries has been rising since 
2014 [5] (€1,964 million in 2016). The latest rises has been attributed to the introduction 
of expensive treatments; starting with the allocation of €30 a million a year for Hepatitis 
C treatment in the public health care system [6, 7]. Since this many high profile 
expensive drugs have been approved, such as eculizumab for paroxysmal nocturnal 
haemoglobinuria and lumacaftor/ivacaftor for cystic fibrosis [5].   
 
Previous studies have described the reimbursement process in Ireland in detail [8-10] 
and examined criteria influencing reimbursement decisions in Ireland following a HTA 
[11]. To summarise, there are two stages to the reimbursement process, which is 
governed by the Supply of Medicines to Health Services Agreement between the 
Government and Irish Pharmaceutical Healthcare Association (IPHA), hereinafter the 
IPHA Agreement. In stage 1, a RR is required for all new medicines following a 
licensing decision. The RR is a short dossier submitted by the drug manufacturer 
detailing the condition and technology, price, regulatory status, placement in therapy, 
comparator(s), clinical evidence and budget impact [12]. The National Centre for 
Pharmacoeconomics (NCPE) assesses the RR within 28 days. There are two outcomes 
from the RR: full HTA not recommended or full HTA recommended. (In some cases a 
HTA is initially recommended at submitted price but is avoided following price 
negotiations). If a HTA is not required, a positive reimbursement recommendation is 
made by the national health service (Health Services Executive, HSE). Stage 2 involves 
a HTA and further engagement with the HSE. The HTA is assessed by the NCPE within 
90 days (excluding clock stops for questions).  The recommendations following a HTA 
are a positive decision to reimburse at applied terms; negative reimbursement decision 
or the decision is referred to the national agency (HSE Drugs Group) who either 
recommends the drug for reimbursement or not.  
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In an academic publication McCullagh and Barry [8] indicate that when appraising a 
RR and deciding if a full HTA is required, the following criteria are considered by the 
NCPE: robustness of clinical efficacy data indicating non-inferiority/superiority to 
comparator while being equal / lower in cost; small eligible population with an unmet 
need and low associated budget impact (less than €0.75 to €1 million per annum) or 
low estimated budget impact, along with existing system infrastructure capable of 
restricting usage. These criteria, however, are not formalised and do not appear on the 
NCPE website, IPHA agreement or any on any other guidance or process 
documentation used by manufacturers, just the academic publication [8]. Also, it is not 
clear how these criteria are weighted in the decision making process. 
 
Whether a HTA is recommended or not has implications for access. As per the IPHA 
Agreement [13], the guidance regarding reimbursement timelines for the RR stage and 
HTA stage are 73 days (28 days RR evaluation plus 45 days to reimbursement) and 163 
days (28 days RR evaluation, 90 days HTA evaluation and 45 days to reimbursement) 
respectively. While the timelines for the RR stage are generally adhered to and 
reimbursement almost guaranteed if no HTA is recommended [8], there are delays in 
the HTA stage because of clock stops during the evaluation of the HTA and delays in 
the further engagement phase which involve price negotiations, with the HSE [14].  
Furthermore, 25% of drugs that undergo a HTA do not get reimbursed [8]. 
 
The RR is a practical tool that aims to balance timely decision making, affordability 
and access. Attempts at balancing access and affordability are not uniquely Irish. For 
example, in England NICE has recently introduced a fast track appraisal process 
suitable for drugs with an incremental cost effective ratio under €10,000 per QALY 
[15]. Elsewhere, there are specific reimbursement routes and considerations for orphan 
drugs in France and Germany for example [16]; for innovation status in Italy and highly 
specialised technologies in England.  
 
Eight years on from the introduction of compulsory RRs and in the absence of formal 
decision-making criteria on the necessity of a HTA, this study examines the factors 





A database was developed combining data from publicly available sources for all drug 
evaluations conducted by the NCPE from January 2010 up to June 2017 (vaccines and 
devices were excluded). An overview of the variables and sources contained in the 
database are summarised in Table 1. Table 2 presents a comparison of drugs 
recommended and not recommended for HTA.  
 
Irish data on patient drug costs were not publicly available from the NCPE website for 
drugs that did not require a HTA and for approximately two thirds of those that 
underwent a HTA. To overcome this, cost data was obtained from the Scottish 
Medicines Consortium (SMC) website and used as a proxy. The SMC data was used as 
a proxy for two reasons. First, the populations are similar in size (5.4m in Scotland [17], 
4.8m in Ireland [18]). Second, the SMC appraise all new licensed medicines and make 
the evaluations publicly available so there was a higher likelihood that the data would 
be available from the SMC compared to other jurisdictions.  Drug cost per patient from 
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the SMC was used as opposed to budget impact data because the latter was often not 
disclosed for confidentiality reasons and while the populations are similar, the 
prevalence of diseases can be different thus impacting transferability [19].  Table 3 
presents a summary of SMC cost data (converted to Euros using annual average 
exchange rates).  
 
2.2 Analysis  
To explore the factors influencing the likelihood that a medicine requires a full HTA, 
descriptive statistics on the data defined above are produced after which an econometric 
analysis is employed. With a binary dependent variable, (HTA (1) or no HTA (0)), a 
logit regression is employed using STATA version 14 [25]. This predicts the 
dichotomous outcome of the dependent categorical variable (HTA) based on the 
explanatory (independent) variables using binomial probability theory.  The 
explanatory variables included here are: year of the review (dummy variable for each 
year), type of reimbursement scheme (dummy variable for each), first in class; 
therapeutic area (dummy variable of each), submission company’s experience, orphan 
disease, reassessment, per year.  The form of logit regression equation is: 
 
logit�𝑝𝑝(𝑥𝑥)� = 𝑙𝑙𝑙𝑙𝑙𝑙 �
𝑝𝑝(𝑥𝑥)
1 − 𝑝𝑝(𝑥𝑥)
� = 𝑎𝑎 +  𝑏𝑏1𝑥𝑥1 + 𝑏𝑏2𝑥𝑥2 + ⋯ 
 
The marginal effects are also estimated using STATA version 14. These measure the 
effect on the conditional mean of the dependent variable of a change in the independent 
variables. This provides a good approximation to the amount of change in the dependent 
variable produced as function of the change in the independent variables, thus are more 
intuitive particular for logit models. 
 
As SMC cost data were only proxies, two econometric analyses were conducted the 
first without SMC cost data on the full data set (n= 296) and the second with SMC cost 
data on the restricted data set (n=212).  
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Table 1: Data Sources & Descriptive Statistics  
Variable Definition Source Description Mean 
 
Std Dev 
HTA HTA recommended (or HTA not 
recommended) 
NCPE website [20] Binary: HTA (1) , No HTA   (0) 0.55 0.5 




Binary variable per area:  Yes (1) , No (0)   
Circulatory 0.11 0.31 
Endocrine 0.13 0.34 
Musculoskeletal 0.07 0.26 
Respiratory 0.07 0.26 
Neoplasm 0.27 0.45 
Infectious disease 0.06 0.23 
Other 0.29 0.45 
Reimbursement 
scheme 
General Medical Services 
(GMS) 
High Technology Scheme (HTS) 
Hospital (it was assumed that all 
IV drugs were reimbursed by 
hospitals) 
NCPE website and in 
monthly PCRS updates 
[20] 
Binary variable per scheme (GMS, HTS, 
Hospital) Yes (1) , No   (0) 
  
GMS 0.30 0.46 
HTS 0.34 0.48 
Hospital 0.36 0.48 
Year Year of outcome of RR NCPE website [20] Binary variable per year (2009-2017) Yes (1) , No   
(0) 
  
2010 0.04 0.20 
2011 0.11 0.31 
2012 0.10 0.31 
2013 0.11 0.32 
2014 0.17 0.38 
2015 0.15 0.35 
2016 0.21 0.41 
2017 0.10 0.31 
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Variable Definition Source Description Mean 
 
Std Dev 
First in class Variable indicates unique 
mechanism of action for 
treatment as designated by the 
FDA in their annual report of 
novel drugs. 
FDA Annual Reports [22] Binary: Yes (1) , No   (0) 0.37 0.48 
Orphan status Drug designated orphan status by 
the European Commission 
Community Register of orphan 
medicines. 
European Commission 
Community Register of 
orphan medicines [23] 
Binary: Yes (1) , No   (0) 0.78 0.41 
New drug Drug designated a new drug if 
not previously evaluated by the 
NCPE. 
NCPE Website [20] Binary: Yes (1) , No   (0) 0.78 0.78 
Experience Variable indicates the experience 
of companies navigating the 
reimbursement process 
measured by the number of RR 
and HTA submissions. 
NCPE Website (count of 
submissions per 




Cost Cost per patient converted to 
Euros using annual exchange 
rates. 
SMC Website [24] Continuous (£ converted to € using average 
annual exchange rates) 
See Table 3 
FDA=Food and Drug Administration, GMS = general medicines scheme, HTA= health technology assessment, NCPE=National Centre for 
Pharmacoeconomics, RR= rapid review, WHO= world health organisation, PCRS=Primary Care Reimbursement Service, PCRS Schemes: General 
Medicines Scheme (GMS): covering drugs that are prescribed and dispensed in community pharmacies. It is means tested and those eligible receive 
free medicines subject to a €2 prescription charge (up to a maximum €20 a month). High Technology Scheme (HTS): covering mainly oral high 
cost drugs that are prescribed in hospitals but dispensed in the community.  Hospital scheme: covering IV drugs prescribed and dispensed in 
hospitals. SMC = Scottish Medicines Consortium.
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Table 2 Comparison of Drugs Recommended and Not Recommended for HTA  
 
 HTA Recommended %  
(n=165) 
HTA Not Recommended % 
(n=137) 
All 55% 45% 
Circulatory  41% 59% 
Endocrine 64% 36% 
Musculoskeletal 62% 38% 
Respiratory 33% 67% 
Neoplasms 88% 12% 
Infectious disease 35% 65% 
Other Areas 33% 67% 
First In Class 73% 27% 
Orphan Disease 78% 22% 
New Drug 52% 48% 
GMS Scheme 36% 64% 
HTDS Scheme 68% 32% 
Hospital Scheme 58% 42% 
Year 2010 50% 50% 
Year 2011 34% 66% 
Year 2012 58% 42% 
Year 2013 36% 64% 
Year 2014 47% 53% 
Year 2015 58% 42% 
Year 2016 68% 32% 
Year 2017 77% 23% 





Table 3 Summary SMC Cost Data (Converted to Euro) 
 
 Average SMC Cost € Std Dev € Sample Size 
All 36,516 61,171 212 
Circulatory  6,921 11,640 22 
Endocrine 64,869 103,231 29 
Musculoskeletal 56,320 147,678 13 
Respiratory 17,217 21,068 13 
Neoplasms 56,875 33,218 63 
Infectious disease 33,269 33,271 15 
Other areas 11,749 20,525 57 
First in class 53,627 78,080 89 
Orphan disease 82,230 92,783 50 
New drug 35,430 65,094 160 
GMS  11,667 73,677 55 
HTS  47,977 51,204 81 
Hospital scheme 42,283 56,513 76 
Year 2010 36,485 45,956 7 
Year 2011 22,981 62,102 19 
Year 2012 24,152 48,267 22 
Year 2013 17,723 24,828 28 
Year 2014 23,053 26,280 38 
Year 2015 32,996 39,448 35 
Year 2016 60,158 95,680 47 
Year 2017 72,714 68,799 16 
Notes: 
GMS=general medicines scheme, HTS=high technology scheme, SMC Costs 
converted from £ sterling to € Euros using annual exchange rates.  








3.1 NCPE Evaluations 2010-2017 
In total 296evaluations, involving a RR, were conducted by the NCPE between January 
2010 and June 2017, in 55% of cases a HTA was recommended (n=163) (Figure 1 and 
Table 2). Table 2 shows that there was an increasing trend of HTAs being 
recommended and that over 70% of first-in-class and orphan drugs were recommended 
for HTA. With regards to therapeutic area, drugs for neoplasm, circulatory and 
musculoskeletal disease were more likely to be recommended for HTA compared to 
other therapeutic areas. Moreover, drugs seeking reimbursement for the High 
Technology and Hospital reimbursement schemes were more likely to attract a HTA 
compared to the general scheme (Table 2).    
 
SMC cost data was available in 212 cases and a HTA was recommended in 62% of 
these cases (n=132). Average annual cost per patient was €36,516 (standard deviation 
€61,171). With regards to therapeutic area, average annual drug costs per patient were 
highest amongst drugs indicated for endocrine, neoplasms and the musculoskeletal 
systems. Average costs for drugs classified as first in class, new and orphan diseases 




3.2 Factors Influencing Rapid Review Outcome 
The logistic regression results reveal therapeutic area (specifically, endocrine, 
musculoskeletal and neoplasms), first in class and orphan disease status are statistically 
significant in influencing the RR outcome (Table 4). Specifically, a drug indicated for 
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the endocrine system is 21% more likely to require a HTA compared to drugs in the 
other therapeutic areas category, holding all else constant.  In addition, drugs indicated 
for musculoskeletal and neoplasm systems are 21% and 41% respectively, more likely 
to require a HTA, than drugs in the other therapeutic area category, holding all else 
constant. Similarly, drugs that are first in class (19%) and those with orphan status 
(15%) are more likely to require a HTA.  
 
As indicated previously, a limitation of the publicly available information used to create 
the data set for this regression was the absence of cost parameters. To overcome this, 
data on annual drug costs per patient were obtained from the SMC website and used as 
a proxy for Ireland. These variables were added to the original logistic regression to 
investigate factors influencing the RR outcome (n=212). Results reveal a positive 
relationship between cost per patient and RR outcome. As costs increase, the likelihood 
of a HTA being recommended increases. Specifically, every €1,000 increase in the 
annual per patient cost of a drug increases the probability of a HTA being requested by 
1%. A drug indicated for the circulatory, endocrine, musculoskeletal system or a 
neoplasm is more likely to require a HTA, than drugs in the other therapeutic areas 
category, holding all else constant.  Meanwhile a drug indicated for infectious diseases 
is less likely to need a HTA, holding all else constant. Estimating the predicted values 
at various cost thresholds (using regression results) indicates that when patient drug 




Table 4 Logistic Regression Results 












































































































LR chi2 101.86 116.99 
Prob > chi2 0.0000 0.0000 
Pseudo R2 0.2501 0.4039 
GMS= general medicines Scheme, HTS= high technology scheme, SMC=Scottish Medicines Consortium.  
Dummy variable reference categories: Other therapeutic area; hospital scheme; and year 2010. 






Previous research elsewhere [26-29] and in Ireland [11] have explored the factors 
influencing reimbursement decisions following a HTA. However, in Ireland 
reimbursement can be secured without a HTA. In the absence of formal and transparent 
guidance around the requirement for a HTA, the factors influencing this decision have 
yet to be explored. This is a particularly important question in Ireland because 45% of 
drugs evaluated do not require a HTA, and for these drugs reimbursement is almost 
guaranteed. Consequently access is much faster for those drugs than when a HTA is 
required. Furthermore, this analysis contributes to the growing international evidence 
base on reimbursement systems.  
 
To analyse the factors influencing whether a HTA is required or not in Ireland, 302 296 
drugs evaluated by the NCPE between 2010 and 2017 were examined and logistic 
regression models were employed. Results of the first logistic regression reveal that 
drugs that are first in-class, for orphan diseases, for cancer and for endocrine and 
musculoskeletal systems are more likely to require a HTA. These results are 
unsurprising as these medicines tend to be high cost and the scientific rigour associated 
with a HTA is required to investigate their cost effectiveness. Another logistic 
regression that included annual proxy drug costs from the SMC (n=212) indicate that 
costs are a factor in deciding whether a HTA is required or not. Specifically, it shows 
that every €1,000 increase in annual drug costs per patient, increases the likelihood of 
a HTA by 1%. In addition, while the endocrine, oncology and musculoskeletal remain 
significant in the second logistic regression, orphan drug status and first in class are no 
longer significant. This may suggest that it is not first-in-class and orphan status per se 
that is driving the need for a HTA but the costs associated with these labels. These 
results indicate that the RR is fit for purpose; drugs that are likely to have a high 
budget impact are recommended for HTA. 
 
This study adds to the literature describing and explaining the factors influencing the 
requirements for a HTA. Specifically, it advances previous studies of the Irish RR 
system [30], by including more observations and augmenting the NCPE database with 
secondary data such as orphan status and proxy drug costs from the SMC. This adds to 
the explanatory power of the logistic regression. In addition, proxy costs allowed for 
exploration of a cost threshold for RR outcomes. The regression results suggest that for 
drugs with annual patient costs greater than €15,000 a HTA is the most likely outcome 
of the RR. However, costs employed are only proxies because Irish cost data are not 
available for drugs that did not require a HTA and for many of those that underwent a 
HTA. We acknowledge this is a limitation of the study.  
 
Furthermore, we acknowledge a better indicator of the cost impact of introducing a new 
drug is the budget impact. Indeed, while not formalised in the reimbursement process, 
previous commentary on Ireland’s HTA process indicate a low budget impact threshold 
of between €0.75 to €1 million per annum is one of the criteria that influences the 
outcome of the RR in Ireland [8]. Unfortunately, Irish budget impact data is not 
available for many of the drugs evaluated. Nor is it easily transferable between 
jurisdictions, so proxy budget impact data from SMC could not be used. Therefore, 




While, McCullagh and Barry [8] outline criteria influencing the outcome of the RR 
(robust clinical data, low budget impact (€0.75 -€1m per year), unmet medical need, 
and systems in place to restrict indication), these are not formalised and lack definition. 
Also, it is not clear how these criteria are weighted in the decision making process. The 
lack of formal criteria coupled with the compulsory nature of RRs means that there is 
often duplication because agency staff are evaluating the same drug twice. Compulsory 
RRs also mean delays in initiating a HTA. For example, is it necessary for very high 
cost drugs such as lumacaftor/ivacaftor for cystic fibrosis to undergo both a RR and 
HTA? Given the new drugs pipeline is dominated by orphan, cancer and specialty 
medicines [31], which this study has shown are more likely to require a HTA to secure 
reimbursement, can the reimbursement process sustain such duplication? Moreover, 
how viable is the RR process in its current format; would an opt-in or opt–out approach 
be a better way to optimise agency resources? However, transparent and formal 
decision criteria would be needed if compulsory RRs were replaced with an opt-in or -
out approach. This would require significant consideration, as well as capacity for 
frequent reviews to avoid criteria becoming “out of date”, together with mechanisms to 
avoid moral hazard or gaming behaviour. Other jurisdictions have developed formal 
criteria for opt-in systems, for example, NICE’s fast track appraisal process is deemed 





As new, innovative medicines are diffused and demand for existing medicines grows 
pressure on reimbursement systems in the EU and beyond will persist. Exploring 
reimbursement approaches and sharing experiences can be meaningful for HTA 
agencies designing and evolving their systems [32], particularly given the shift towards 
value based frameworks for reimbursement [33].  
 
This study describes the RR process employed in Ireland and indicates the factors 
influencing the requirement of a HTA to secure reimbursement, namely therapeutic 
area, first in class, orphan status and drug costs. These results, coupled with current and 
expected future trends of high cost drugs and delays in access to medicines, suggest 
better management for their introduction is warranted. Establishing formal decision-
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